Purpose: To analyze the medical management of primary open-angle glaucoma (POAG)
and ocular hypertension (OHT) and the placement of fixed-drug combination drugs (FDC) in …

Background Poor persistence with glaucoma therapy can lead to disease progression and
subsequent blindness. Persistence with second-line glaucoma combination treatment in a …

Background The aim of study was to understand anti-glaucoma fixed dose drug combination
use in real-world settings, focussing on drug selection, repeated prescription of the same …

Objective We hypothesize that there may be an inappropriate overuse of initial combination
therapy in patients with glaucoma and in those who are glaucoma suspects. To test this …

Purpose: To study the intraocular pressure (IOP)-lowering effect of adding a third or a fourth
antiglaucoma medication to preexisting antiglaucoma medical therapy, for a follow-up …

Ocular hypotensive agents are the only approved pharmacotherapy for glaucoma. Despite
significant advances during the past two decades, a large proportion of glaucoma patients …

Background Glaucoma is an optic neuropathy associated with characteristic structural
damage to the optic nerve and associated visual dysfunction that may be caused by various …

As a progressive eye disease, glaucoma is on every optometrist's radar, especially primary
open-angle glaucoma (POAG), the most common form.(1-10) Research estimates it will …

ABSTRACT Introduction Fixed dose combinations (FCs) represent a potentially valuable
treatment strategy in glaucoma management. Fixed combinations not only improve …

Background. The aim of this study was to compare the daily costs and cost effectiveness of
fixed combination glaucoma drugs in China. Methods. This study included the following …